Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with Pentamidine

Lejon, V.; Legros, D.; Savignoni, A.; Gastellu Etchegorry, M.; Mbulamberi, D.; Büscher, P.

oai:dspace.itg.be:10390/207

Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with Pentamidine

Authors: V. Lejon
D. Legros
A. Savignoni
M. Gastellu Etchegorry
D. Mbulamberi
P. Büscher
Publication date: 2003
Publisher
Doi

Abstract

In a clinical trial on efficacy of Pentamidine in second stage Trypanosoma brucei gambiense patients with /=4 and LATEX/T.b. gambiense positive CSF, were associated with treatment failure.Detection of intrathecal IgM synthesis is valuable for assessment of brain involvement and treatment decision

Similar works

Full text

Tropmed Central Antwerp

oai:dspace.itg.be:10390/207

Last time updated on 30/09/2015

This paper was published in Tropmed Central Antwerp.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.